McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

McKesson Corporation

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

US Pharmaceutical Capital Expenditures

US Pharmaceutical Capital Expenditures % Chg.

US Pharmaceutical Capital Expenditures Common Size

Prescription Technology Solutions Capital Expenditures

Prescription Technology Solutions Capital Expenditures % Chg.

Prescription Technology Solutions Capital Expenditures Common Size

Medical Surgical Solutions Capital Expenditures

Medical Surgical Solutions Capital Expenditures % Chg.

Medical Surgical Solutions Capital Expenditures Common Size

International Capital Expenditures

International Capital Expenditures % Chg.

International Capital Expenditures Common Size

Other Capital Expenditures

Other Capital Expenditures % Chg.

Other Capital Expenditures Common Size

Total Capital Expenditures

Total Capital Expenditures Common Size

Total Capital Expenditures % Chg.

Capital Expenditures

Prescription Technology Solutions Operating Profit

Prescription Technology Solutions Operating Profit % Chg.

Prescription Technology Solutions Operating Profit Common Size

Medical Surgical Solutions Operating Profit

Medical Surgical Solutions Operating Profit % Chg.

Medical Surgical Solutions Operating Profit Common Size

US Pharmaceutical Operating Profit

US Pharmaceutical Operating Profit % Chg.

US Pharmaceutical Operating Profit Common Size

International Operating Profit

International Operating Profit % Chg.

International Operating Profit Common Size

Other EBIT

Other EBIT % Chg.

Other EBIT Common Size

Total EBIT

Total EBIT Common Size

Total EBIT % Chg.

Prescription Technology Solutions Revenue

Prescription Technology Solutions Revenue % Chg.

Prescription Technology Solutions Revenue Common Size

Medical Surgical Solutions Revenue

Medical Surgical Solutions Revenue % Chg.

Medical Surgical Solutions Revenue Common Size

US Pharmaceutical Revenue

US Pharmaceutical Revenue % Chg.

US Pharmaceutical Revenue Common Size

International Revenue

International Revenue % Chg.

International Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

North American Pharmaceutical Operating Profit

North American Pharmaceutical Operating Profit % Chg.

North American Pharmaceutical Operating Profit Common Size

Oncology & Multispecialty Operating Profit

Oncology & Multispecialty Operating Profit % Chg.

Oncology & Multispecialty Operating Profit Common Size

Other Segment Operating Profit

Other Segment Operating Profit % Chg.

Other Segment Operating Profit Common Size

North American Pharmaceutical Revenue

North American Pharmaceutical Revenue % Chg.

North American Pharmaceutical Revenue Common Size

Oncology & Multispecialty Revenue

Oncology & Multispecialty Revenue % Chg.

Oncology & Multispecialty Revenue Common Size

Other Segment Revenue

Other Segment Revenue % Chg.

Other Segment Revenue Common Size

Revenue	LTM	Mar '25	Mar '24
Prescription Technology Solutions Revenue	5,520	5,216	4,769
Medical Surgical Solutions Revenue	11,450	11,386	11,313
US Pharmaceutical Revenue	—	327,717	278,739
International Revenue	—	14,721	14,130
Other Revenue	370,124	11	—
Total Revenue	387,094	359,051	308,951

EBIT	LTM	Mar '25	Mar '24
Prescription Technology Solutions Operating Profit	964	875	835
Medical Surgical Solutions Operating Profit	937	773	952
US Pharmaceutical Operating Profit	—	4,002	2,786
International Operating Profit	—	-213	319
Other EBIT	3,357	-1,015	-983
Total EBIT	5,258	4,422	3,909

Capital Expenditures	LTM	Mar '25	Mar '24
US Pharmaceutical Capital Expenditures	—	241	193
Prescription Technology Solutions Capital Expenditures	—	11	31
Medical Surgical Solutions Capital Expenditures	—	163	159
International Capital Expenditures	—	107	75
Other Capital Expenditures	—	15	-27
Total Capital Expenditures	512	537	431